CIMBALA@BIONET-20.ARPA (03/19/88)
From: Jim.Cassatt@BIONET-20.ARPA
Return-Path: <@CUNYVM.CUNY.EDU:CZJ@NIHCU.BITNET>
Received: from CUNYVM.CUNY.EDU by BIONET-20.ARPA with TCP; Fri 18 Mar 88 06:58:36-PST
Received: from NIHCU.BITNET by CUNYVM.CUNY.EDU ; Fri, 18 Mar 88 10:00:30 EST
To: science-resources@bionet-20.arpa
From: CZJ%NIHCU.BITNET@CUNYVM.CUNY.EDU
Date: Fri, 18 Mar 88 09:59:07 EST
Attached is the March 18, 1988 NIH Guide to Grants and Contracts.
Included is the Table of Contents and Announcements of Interest to
the Molecular Biological community.
Jim Cassatt
--------------------------------------------------------------------
Vol. 17, No. 10, March 18, 1988
NOTICES
PUBLIC HEARINGS TO BE HELD BY THE NATIONAL KIDNEY AND UROLOGIC
DISEASES ADVISORY BOARD .................................(84/115)........... 1
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES
NATIONAL RESEARCH SERVICE INDIVIDUAL POSTDOCTORAL FELLOWSHIP
AND SENIOR FELLOWSHIP AWARDS LETTERS OF REFERENCE .......(118/172).......... 1
Division of Research Grants
Index: DIVISION OF RESEARCH GRANTS
REFERENCE LETTERS FOR RESEARCH GRANT APPLICATIONS .......(175/197).......... 2
Division of Research Grants
Index: DIVISION OF RESEARCH GRANTS
DATED ANNOUNCEMENTS (RFPs AND RFAs)
CLONING AND SEQUENCING OF IMMUNODEFICIENCY VIRUS (RFP) ..(203/236).......... 2
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
MASTER AGREEMENT FOR THE CLINICAL EVALUATION OF .........(241/331).......... 3
INVESTIGATIONAL ANTIEPILEPTIC DRUGS (RFP)
National Institute of Neurological and Communicative Disorders
and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE
KIDNEY DISEASE OF DIABETES MELLITUS: NEW BASIC STUDIES OF THE PATHOGENETIC
MECHANISMS AND CLINICAL AND EPIDEMIOLOGIC FEATURES (RFA) ...(334/447)....... 4
National Institute of Diabetes and Digestive and (485/782)
Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES
ERRATUM
ROLE OF GLYCATION IN AGING AND DIABETES ....................(451/479)....... 5
National Institute on Aging and
National Institute of Diabetes and Digestive and Kidney Diseases
Index: AGING; DIABETES AND DIGESTIVE AND KIDNEY DISEASES
NATIONAL RESEARCH SERVICE INDIVIDUAL POSTDOCTORAL FELLOWSHIP
AND SENIOR FELLOWSHIP AWARDS LETTERS OF REFERENCE
P.T. 22; K.W. 0720005, 1014002
Division of Research Grants
The NIH is working to reduce the time required for completion of the receipt,
referral, review, and award of individual postdoctoral fellowship (F32) and
senior fellowship (F33) applications. The goal is to cut the current time of
eight to nine months in half. Accomplishing this goal would benefit
candidates and their sponsors by giving them more time for planning future
research training activities.
To help expedite the review process, NIH is now requiring that at least three
completed, sealed letters of reference be submitted with each individual
fellowship and senior fellowship application.
Four copies of the reference forms are included in each fellowship application
kit. Candidates should:
1. Send these forms to their referees well in advance of the application
submission date, and advise the referees to complete the form and return it to
the candidate in a sealed envelope as soon as possible;
2. Request reference reports only from individuals who will be able to return
them in time for the application submission. Consider any factor (e.g.,
illness or overseas sabbatical, etc.) that might cause an inordinate delay;
3. Choose individuals, other than the sponsor of the application, who can
make the most meaningful comments about the candidate's qualifications for a
research career;
4. If applicable, include a reference from the current mentor or immediate
supervisor. If not submitting a reference from the thesis advisor or chief of
service, explain why in Item 23 of the application;
5. Where possible, select at least one respondent who is not in the
candidate's current department; and
1
6. Select graduate or medical school referees rather than those from
undergraduate schools.
To protect the utility and confidentiality of reference letters, candidates
are asked not to open the envelopes. The sealed envelopes should be attached
to the original application.
Applications with fewer than three references will be returned. Candidates
reapplying (competing continuations or revised applicants) must submit new
reference forms to facilitate the expedited review process.
These procedures are effective as of the May 10, 1988, receipt deadline.
REFERENCE LETTERS FOR RESEARCH GRANT APPLICATIONS
P.T. 34; K.W. 1014002
Division of Research Grants
Applications for the Research Career Development Award (RCDA) and the First
Independent Research Support and Transition (FIRST) Award require letters of
reference. To expedite the referral and review process, the NIH is now asking
that applicants include these reference letters with the submitted application
package.
Therefore, RCDA applicants should send the reference forms included in the PHS
398 kit to their referees well in advance of the application submission and
advise them to complete the forms and return them to the applicant in sealed
envelopes as soon as possible. Similarly, FIRST applicants should request
reference letters early so that these may be submitted with the applications.
To protect the utility and confidentiality of reference letters, applicants
are asked not to open the sealed envelopes. The sealed envelopes should be
attached to the original applications. (This same procedure for submission of
reference letters is now being used for individual and senior National
Research Service Award fellowship applications.) These procedures are
effective as of the June 1, 1988, receipt deadline.
DATED ANNOUNCEMENTS (RFPs AND RFAs)
CLONING AND SEQUENCING OF IMMUNODEFICIENCY VIRUS
RFP AVAILABLE: NIAID-AIDSP-88-27
P.T. 34; K.W. 1002045, 0755045, 0755040, 0780005
National Institute of Allergy and Infectious Diseases
The NIAID, NIH, has a requirement for molecular cloning and nucleotide
sequencing of five (5) immunodeficiency virus isolates the first year and ten
(10) per year thereafter. From seed stocks of virus provided by NIAID, the
Contractor shall grow sufficient volumes of infected peripheral blood
lymphocytes of appropriate cell line to generate at least 200 micrograms of
Hirt supernatant DNA or sufficient proviral DNA for molecular cloning
purposes.
This NIAID-sponsored project will take five years to complete. A
cost-reimbursement contract is anticipated. Three awards are expected to be
made. This is a new requirement. RFP NIH-NIAID-AIDSP-88-27 will be issued
o/a March 22, 1988 with a closing date for receipt of proposals set for May
12, 1988.
To receive a copy of the RFP, please send two self-addressed mailing labels
to:
Dorothy Tyler, Contracting Officer
Contract Management Branch, NIAID
National Institutes of Health
Westwood Bldg., Room 707
5333 Westbard Avenue
Bethesda, Maryland 20892
All responsible sources may submit a proposal which will be considered by
NIAID. This advertisement does not commit the government to award a contract.
KIDNEY DISEASE OF DIABETES MELLITUS: NEW BASIC STUDIES OF THE PATHOGENETIC
MECHANISMS AND CLINICAL AND EPIDEMIOLOGIC FEATURES
RFA AVAILABLE: NIDDK-88-12
P.T. 34; K.W. 0715075, 0785095, 0765035, 1003002, 1002059, 0710070, 0785055
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date: July 15, 1988
The Division of Kidney, Urologic and Hematologic Diseases (DKUHD) of the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
announces the availability of a Request for Applications (RFA) for studies
concerned with Kidney Disease of Diabetes Mellitus.
BACKGROUND
Renal diseases leading to failure that results in replacement therapy
represent an important public health problem. Data from the Health Care
Financing Administration (HCFA) indicate that in l986 over 90,000 patients
received dialysis care from Medicare-certified providers; over 30,000 new
patients began dialysis; more than l5,000 patients died, and over 9,000 end
stage renal disease (ESRD) patients received kidney transplants. The largest
single cause of renal disease is now diabetes mellitus and the number of
patients with ESRD due to kidney disease of diabetes mellitus has risen
steadily over the last decade. At present, nearly 30 percent of new patients
entering the ESRD program have kidney disease of diabetes mellitus. Since
this number is increasing at a rate of approximately two percent annually,
within the next decade this will likely account for more than 50 percent of
all patients in the ESRD program. Thus, kidney disease of diabetes mellitus,
being the predominant cause of ESRD in the United States, represents a
significant and growing problem. However, the pathogenesis remains
controversial, therefore prevention and treatment of this complication
requires intensive investigation. Indeed, comprehensive studies using state
of the art approaches and methodology are needed in a concerted effort to help
define the mechanisms underlying the initiation and evolution, and to identify
approaches to prevent this complication.
RESEARCH OBJECTIVES AND SCOPE
The overall goal of the RFA is to encourage new studies and new investigators
to enter this field to broaden the base of research disciplines addressing
issues pertinent to kidney disease of diabetes mellitus. The RFA is intended
to stimulate the development and submission of research proposals aimed at
understanding the pathogenetic mechanisms and the development of diagnostic
measures and approaches to effective prevention, control and treatment. The
scope of these projects is intended to include studies of the biochemistry,
physiology, pathology, immunology and clinical and epidemiological features,
including studies of glomerular and tubular structure and function; mechanisms
operative in the genesis and early morphological and/or other markers of
progression of the glomerular injury in humans and experimental models;
genetic markers, genetically determined susceptibility, and environmental
factors that contribute to the risk of diabetic renal disease; mechanisms that
mediate early glomerular hemodynamic abnormalities; consequence of sustained
microcirculatory abnormalities; prevention- interventional strategies; markers
of progressive renal disease in renal allografts; study and approaches for the
interpretation of confounded factors, etc.
MECHANISM OF SUPPORT
Support for this program will be through the grant-in-aid mechanism and will
be governed by the current policies applicable to such grant programs of the
National Institutes of Health. New applications may be submitted for
traditional, individual research-project grants (RO1s) only. Although plans
4
for Fiscal Year 1989 include approximately $3.5 million for the total (direct
and indirect) costs of this program, the funding of applications submitted in
response to this RFA is contingent on the actual availability of funds, and
receipt of applications of sufficient scientific merit, as determined by the
rigorous standards of NIH Study Section review. It is anticipated that 10 -
15 awards will be made, for up to 5 years under this program. The specific
amounts to be funded will depend on the merit and scope of the applications
received. Furthermore, since a variety of approaches would represent valid
responses to this announcement, it is anticipated that there will be a range
of costs among individual awards. Awards in response to this announcement
will be made to foreign institutions for research of unusual merit and
promise, and in accordance with PHS policy governing such awards.
APPLICATIONS AND REVIEW PROCEDURES
Applications in response to this RFA will be reviewed for scientific and
technical merit by an Initial Review Group which will be convened by the
Division of Extramural Activities, NIDDK, solely to review these applications.
Upon receipt, applications will be evaluated for their responsiveness to the
objectives of the RFA. If an application is judged unresponsive at this
stage, the applicant will be contacted and given the opportunity to withdraw
the application or have it considered for the regular Research Grant Program
of the NIH. Should the proposal submitted in response to the RFA be
substantially similar to a research grant application already under
consideration at the NIH, the applicant will be asked to withdraw either
application. Simultaneous submission of identical applications will not be
allowed.
Funding decisions will be based on recommendations by the Initial Review Group
and by the National Diabetes and Digestive and Kidney Diseases Advisory
Council, and relevance to the Objectives and Scope of the RFA. Applicants
should request a start date of March 1, 1989.
The RFA label (found in the 9/86 revision of application form PHS 398) must be
affixed to the bottom of the face page of the original copy of the
application. Failure to use this label could result in delayed processing of
your application such that it will not reach the review committee in time for
review.
For further information and copies of the complete RFA, please contact:
Gladys H. Hirschman, M.D.
Director, Chronic Renal Disease Program (DKUHD)
NIDDK, National Institutes of Health
Westwood Building, Room 621
Bethesda, Maryland 20892
Telephone: (301) 496-7571
ERRATUM
-------